Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Benitez Fuentes, Javier David, de Luna Aguilar, Alicia, Jimenez Ortega, Alejandro Francisco, Flores Navarro, Paloma, Bartolomé Arcilla, Jorge, Baos Muñoz, Elvira, Delgado-Iribarren García-Campero, Alberto, Gil Useros, Sara, Martinez Capella, Ignacio, Llorente Sanz, Laura, Torrego Ellacuría, Macarena, Pérez Segura, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816496/
https://www.ncbi.nlm.nih.gov/pubmed/36636471
http://dx.doi.org/10.12688/f1000research.110268.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816496/
https://www.ncbi.nlm.nih.gov/pubmed/36636471
http://dx.doi.org/10.12688/f1000research.110268.2

Ejemplares similares